Cencora, Inc. (COR) P/E Ratio History
ExpensiveTrading at 34.1x vs 5Y avg 24.3x · 90th percentile · Material premium to history · Data 1995–2026
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Cencora, Inc. (COR) trades at a price-to-earnings ratio of 34.1x, with a stock price of $271.83 and trailing twelve-month earnings per share of $13.04.
The current P/E is 40% above its 5-year average of 24.3x. Over the past five years, COR's P/E has ranged from a low of 13.3x to a high of 40.6x, placing the current valuation at the 90th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, COR trades at a 54% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, COR commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our COR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
COR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
COR P/E vs Peers
Drug Wholesalers and Distributors peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $90B | 19.6 | - | +49% | |
| $52B | 34.4 | - | +87%Best | |
| $9B | 24.4 | 7.75 | +7% | |
| $125B | 70.7 | - | -62% | |
| $364B | 30.3 | - | -15% | |
| $74B | 12.6Lowest | - | +83% | |
| $84B | 13.2 | 0.63Best | +29% | |
| $22B | 22.3 | - | +14% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
COR Historical P/E Data (1995–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $314.07 | $13.04 | 24.1x | -25% |
| FY2026 Q1 | Dec 31 2025 | $337.75 | $8.32 | 40.6x | +26% |
| FY2025 Q4 | - | $312.53 | $7.95 | 39.3x | +22% |
| FY2025 Q3 | Jun 30 2025 | $299.85 | $9.72 | 30.9x | -4% |
| FY2025 Q2 | Mar 31 2025 | $278.09 | $8.62 | 32.3x | +0% |
| FY2025 Q1 | - | $224.68 | $7.03 | 32.0x | -1% |
| FY2024 Q4 | Sep 30 2024 | $225.08 | $7.51 | 30.0x | -7% |
| FY2024 Q3 | Jun 30 2024 | $225.30 | $9.21 | 24.5x | -24% |
| FY2024 Q2 | Mar 31 2024 | $242.99 | $9.14 | 26.6x | -18% |
| FY2024 Q1 | Dec 31 2023 | $205.38 | $9.18 | 22.4x | -31% |
| FY2023 Q4 | Sep 30 2023 | $179.97 | $8.53 | 21.1x | -35% |
| FY2023 Q3 | Jun 30 2023 | $192.43 | $8.21 | 23.4x | -27% |
| FY2023 Q2 | Mar 31 2023 | $160.11 | $7.78 | 20.6x | -36% |
| FY2023 Q1 | Dec 31 2022 | $165.71 | $8.24 | 20.1x | -38% |
| FY2022 Q4 | Sep 30 2022 | $135.33 | $8.04 | 16.8x | -48% |
| FY2022 Q3 | - | $141.48 | $8.72 | 16.2x | -50% |
| FY2022 Q2 | - | $154.71 | $8.20 | 18.9x | -41% |
| FY2022 Q1 | Dec 31 2021 | $132.89 | $7.71 | 17.2x | -47% |
| FY2021 Q4 | - | $119.45 | $7.39 | 16.2x | -50% |
| FY2020 Q3 | - | $100.77 | $7.58 | 13.3x | -59% |
| FY2020 Q2 | - | $88.50 | $7.60 | 11.6x | -64% |
| FY2020 Q1 | - | $85.02 | $3.09 | 27.5x | -15% |
| FY2019 Q4 | Sep 30 2019 | $82.33 | $4.03 | 20.4x | -37% |
| FY2019 Q3 | Jun 30 2019 | $85.26 | $4.47 | 19.1x | -41% |
| FY2019 Q2 | Mar 31 2019 | $79.52 | $4.29 | 18.5x | -43% |
| FY2019 Q1 | Dec 31 2018 | $74.40 | $5.45 | 13.7x | -58% |
| FY2018 Q4 | Sep 30 2018 | $92.22 | $7.51 | 12.3x | -62% |
| FY2018 Q3 | Jun 30 2018 | $85.27 | $5.09 | 16.8x | -48% |
| FY2018 Q2 | Mar 31 2018 | $86.21 | $4.07 | 21.2x | -34% |
| FY2018 Q1 | Dec 31 2017 | $91.82 | $4.64 | 19.8x | -39% |
| FY2017 Q4 | Sep 30 2017 | $82.75 | $1.85 | 44.7x | +39% |
| FY2017 Q3 | Jun 30 2017 | $94.53 | $3.83 | 24.7x | -23% |
| FY2017 Q2 | Mar 31 2017 | $88.50 | $5.15 | 17.2x | -47% |
| FY2017 Q1 | Dec 31 2016 | $78.19 | $5.97 | 13.1x | -59% |
| FY2016 Q4 | Sep 30 2016 | $80.78 | $6.31 | 12.8x | -60% |
| FY2016 Q3 | - | $79.32 | $7.24 | 11.0x | -66% |
| FY2016 Q2 | - | $86.55 | $6.58 | 13.2x | -59% |
| FY2016 Q1 | - | $103.71 | $1.57 | 66.1x | +105% |
| FY2015 Q1 | Dec 31 2014 | $90.16 | $0.08 | 1081.1x | +3252% |
| FY2014 Q4 | - | $77.30 | $1.17 | 65.9x | +104% |
| FY2014 Q3 | Jun 30 2014 | $72.66 | $1.10 | 65.9x | +104% |
| FY2014 Q2 | Mar 31 2014 | $65.59 | $1.87 | 35.1x | +9% |
| FY2014 Q1 | - | $70.31 | $1.30 | 54.1x | +68% |
| FY2013 Q4 | Sep 30 2013 | $61.10 | $1.83 | 33.4x | +4% |
| FY2013 Q3 | Jun 30 2013 | $55.83 | $2.27 | 24.6x | -24% |
| FY2013 Q2 | Mar 31 2013 | $51.45 | $2.27 | 22.7x | -30% |
| FY2013 Q1 | Dec 31 2012 | $43.18 | $2.89 | 14.9x | -54% |
| FY2012 Q4 | Sep 30 2012 | $38.71 | $2.80 | 13.8x | -57% |
| FY2012 Q3 | Jun 30 2012 | $39.35 | $2.68 | 14.7x | -54% |
| FY2012 Q2 | Mar 31 2012 | $39.66 | $2.63 | 15.1x | -53% |
| FY2012 Q1 | Dec 31 2011 | $37.19 | $2.59 | 14.4x | -55% |
| FY2011 Q4 | Sep 30 2011 | $37.27 | $2.54 | 14.7x | -55% |
| FY2011 Q3 | - | $41.40 | $2.50 | 16.6x | -49% |
| FY2011 Q2 | - | $39.56 | $2.41 | 16.4x | -49% |
| FY2011 Q1 | Dec 31 2010 | $34.12 | $2.27 | 15.0x | -53% |
| FY2010 Q4 | - | $30.66 | $2.22 | 13.8x | -57% |
| FY2010 Q3 | Jun 30 2010 | $31.75 | $2.16 | 14.7x | -54% |
| FY2010 Q2 | Mar 31 2010 | $28.92 | $1.99 | 14.5x | -55% |
| FY2010 Q1 | - | $26.07 | $1.83 | 14.2x | -56% |
| FY2009 Q4 | Sep 30 2009 | $22.38 | $1.67 | 13.4x | -58% |
| FY2009 Q3 | - | $17.74 | $1.59 | 11.2x | -65% |
| FY2009 Q2 | - | $16.33 | $0.85 | 19.2x | -40% |
| FY2009 Q1 | Dec 31 2008 | $17.83 | $0.79 | 22.6x | -30% |
| FY2008 Q4 | - | $18.82 | $0.76 | 24.8x | -23% |
| FY2008 Q3 | Jun 30 2008 | $20.00 | $0.65 | 30.8x | -5% |
| FY2008 Q2 | Mar 31 2008 | $20.49 | $1.34 | 15.3x | -53% |
| FY2008 Q1 | Dec 31 2007 | $22.44 | $1.27 | 17.7x | -45% |
| FY2007 Q4 | Sep 30 2007 | $22.67 | $1.25 | 18.1x | -44% |
| FY2007 Q3 | Jun 30 2007 | $24.00 | $1.30 | 18.5x | -43% |
| FY2007 Q2 | Mar 31 2007 | $25.59 | $1.24 | 20.6x | -36% |
| FY2007 Q1 | Dec 31 2006 | $21.81 | $1.21 | 18.0x | -44% |
| FY2006 Q4 | Sep 30 2006 | $21.93 | $1.13 | 19.4x | -40% |
| FY2006 Q3 | Jun 30 2006 | $20.34 | $1.00 | 20.3x | -37% |
| FY2006 Q2 | Mar 31 2006 | $23.42 | $0.94 | 24.9x | -23% |
| FY2006 Q1 | Dec 31 2005 | $20.09 | $0.86 | 23.4x | -28% |
| FY2005 Q4 | Sep 30 2005 | $18.75 | $0.77 | 24.4x | -24% |
| FY2005 Q3 | - | $16.77 | $0.80 | 21.0x | -35% |
| FY2005 Q2 | - | $13.90 | $0.84 | 16.5x | -49% |
| FY2005 Q1 | Dec 31 2004 | $14.23 | $0.91 | 15.6x | -52% |
| FY2004 Q4 | - | $13.03 | $1.00 | 13.0x | -60% |
| FY2004 Q3 | Jun 30 2004 | $14.50 | $1.05 | 13.8x | -57% |
| FY2004 Q2 | Mar 31 2004 | $13.26 | $1.02 | 13.0x | -60% |
| FY2004 Q1 | Dec 31 2003 | $13.62 | $0.97 | 14.0x | -56% |
| FY2003 Q4 | - | $13.11 | $0.94 | 13.9x | -57% |
| FY2003 Q3 | Jun 30 2003 | $16.82 | $0.90 | 18.7x | -42% |
| FY2003 Q2 | Mar 31 2003 | $12.74 | $0.86 | 14.8x | -54% |
| FY2003 Q1 | - | $13.17 | $0.82 | 16.1x | -50% |
| FY2002 Q4 | Sep 30 2002 | $17.33 | $0.77 | 22.5x | -30% |
| FY2002 Q3 | Jun 30 2002 | $18.44 | $0.68 | 27.1x | -16% |
| FY2002 Q2 | Mar 31 2002 | $16.57 | $0.61 | 27.2x | -16% |
| FY2002 Q1 | Dec 31 2001 | $15.42 | $0.53 | 29.1x | -10% |
| FY2001 Q4 | Sep 30 2001 | $17.21 | $0.50 | 34.4x | +7% |
| FY2001 Q3 | Jun 30 2001 | $13.43 | $0.51 | 26.3x | -18% |
| FY2001 Q2 | Mar 31 2001 | $11.90 | $0.50 | 23.8x | -26% |
| FY2001 Q1 | Dec 31 2000 | $12.25 | $0.49 | 25.0x | -22% |
| FY2000 Q4 | Sep 30 2000 | $11.40 | $0.47 | 24.3x | -25% |
| FY2000 Q3 | Jun 30 2000 | $7.52 | $0.39 | 19.5x | -39% |
| FY2000 Q2 | Mar 31 2000 | $3.64 | $0.36 | 10.1x | -69% |
| FY2000 Q1 | Dec 31 1999 | $3.68 | $0.34 | 10.8x | -66% |
| FY1999 Q4 | - | $5.75 | $0.33 | 17.6x | -46% |
| FY1999 Q3 | Jun 30 1999 | $6.19 | $0.30 | 20.9x | -35% |
| FY1999 Q2 | Mar 31 1999 | $8.29 | $0.28 | 29.1x | -10% |
| FY1999 Q1 | - | $7.88 | $0.27 | 29.3x | -9% |
| FY1998 Q4 | Sep 30 1998 | $6.60 | $0.26 | 25.7x | -20% |
| FY1998 Q3 | - | $7.97 | $0.31 | 25.4x | -21% |
| FY1998 Q2 | - | $7.29 | $0.26 | 27.9x | -13% |
| FY1998 Q1 | Dec 31 1997 | $7.07 | $0.24 | 29.9x | -7% |
| FY1997 Q4 | - | $7.09 | $0.22 | 31.7x | -2% |
| FY1997 Q3 | Jun 30 1997 | $6.05 | $0.22 | 27.4x | -15% |
| FY1997 Q2 | Mar 31 1997 | $5.31 | $0.21 | 25.8x | -20% |
| FY1997 Q1 | - | $5.85 | $0.21 | 28.4x | -12% |
| FY1996 Q4 | Sep 30 1996 | $5.40 | $0.19 | 27.9x | -14% |
| FY1996 Q3 | Jun 30 1996 | $4.03 | $0.18 | 22.6x | -30% |
| FY1996 Q2 | Mar 31 1996 | $4.00 | $0.18 | 22.2x | -31% |
| FY1996 Q1 | Dec 31 1995 | $4.00 | $0.18 | 22.3x | -31% |
| FY1995 Q4 | Sep 30 1995 | $3.27 | $0.04 | 88.4x | +174% |
Average P/E for displayed period: 32.2x
Full Stock Analysis
Deep dive into COR consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
31+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
COR — Frequently Asked Questions
Quick answers to the most common questions about buying COR stock.
What is COR's P/E ratio?
Cencora, Inc. (COR) trailing twelve-month P/E ratio is 34.1x, based on TTM diluted EPS of $13.04. The 5-year average P/E is 24.3x and the historical range spans 13.3x to 40.6x.
Is COR stock overvalued or undervalued?
COR trades at 34.1x P/E, above its 5-year average of 24.3x. The 90th percentile ranking within the 13.3x–40.6x historical range indicates a premium to historical valuation.
Is COR stock expensive?
Yes, COR is expensive relative to its own history. The current P/E of 34.1x is above the 5-year average of 24.3x and also above the Healthcare sector median of 22.1x. The stock sits at the 90th percentile of its 5-year valuation range.
What is COR's historical P/E range?
Over the past 5 years, COR's P/E ratio has ranged from 13.3x to 40.6x, with a median of 23.4x and an average of 24.3x. The current P/E of 34.1x places the stock at the 90th percentile of this range. Full historical data spans 1995–2026.
How does COR's P/E compare to the S&P 500?
COR trades at 34.1x P/E versus the S&P 500 median of 24.4x. The 40% premium to the market typically reflects higher expected earnings growth or quality.
How does COR's valuation compare to Healthcare peers?
Cencora, Inc. P/E of 34.1x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is COR's PEG ratio?
COR PEG ratio is N/A, based on a P/E of 34.1x and EPS growth of 5.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is COR's earnings yield?
COR earnings yield is 2.93%, the inverse of its 34.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.